Brokerages expect AxoGen, Inc. (NASDAQ:AXGN) to report earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for AxoGen’s earnings, with estimates ranging from ($0.11) to ($0.07). AxoGen posted earnings per share of ($0.10) during the same quarter last year, which suggests a positive year over year growth rate of 10%. The business is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, February 28th.
On average, analysts expect that AxoGen will report full year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.31). For the next year, analysts forecast that the company will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.32) to ($0.20). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover AxoGen.
Several equities research analysts recently commented on AXGN shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of AxoGen in a report on Friday, January 5th. Jefferies Group started coverage on AxoGen in a report on Thursday, November 30th. They set a “buy” rating and a $35.00 target price on the stock. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Lake Street Capital raised their target price on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 21st. Finally, Leerink Swann raised their target price on AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.33.
A number of hedge funds and other institutional investors have recently modified their holdings of AXGN. Schwab Charles Investment Management Inc. grew its stake in AxoGen by 33.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 51,300 shares of the medical equipment provider’s stock valued at $860,000 after purchasing an additional 13,000 shares in the last quarter. Bank of New York Mellon Corp grew its stake in AxoGen by 80.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 160,354 shares of the medical equipment provider’s stock valued at $2,685,000 after purchasing an additional 71,609 shares in the last quarter. Wells Fargo & Company MN grew its stake in AxoGen by 17.2% during the 2nd quarter. Wells Fargo & Company MN now owns 46,745 shares of the medical equipment provider’s stock valued at $783,000 after purchasing an additional 6,848 shares in the last quarter. Alliancebernstein L.P. acquired a new stake in AxoGen during the 2nd quarter valued at approximately $317,000. Finally, Ameriprise Financial Inc. acquired a new stake in AxoGen during the 2nd quarter valued at approximately $1,412,000. Hedge funds and other institutional investors own 65.94% of the company’s stock.
Shares of AxoGen (NASDAQ:AXGN) opened at $25.90 on Wednesday. The company has a market capitalization of $864.28, a PE ratio of -64.75 and a beta of 0.12. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. AxoGen has a twelve month low of $9.55 and a twelve month high of $31.70.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/07/0-09-earnings-per-share-expected-for-axogen-inc-axgn-this-quarter.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.